Description

Ionis Pharmaceuticals: How TRYNGOLZA, DAWNZERA And A $2B Pipeline Opportunity Are Reshaping Its Growth Trajectory!

Ionis Pharmaceuticals delivered a year marked by significant commercial and developmental milestones in 2025, reflecting its transition toward a fully integrated commercial-stage biotechnology company. The company launched two independent therapies: TRYNGOLZA, targeting familial chylomicronemia syndrome (FCS), and DAWNZERA, for hereditary angioedema (HAE). TRYNGOLZA’s launch exceeded expectations with steady quarterly revenue growth, reaching $108 million in full-year product sales driven by an expanding prescriber base spanning cardiologists, endocrinologists, and lipidologists. Early adoption of DAWNZERA is also progressing well, supported by patient-friendly features, including a self-administered auto-injector and a free trial program with complete conversion to paid therapy, yielding $8 million in product sales for 2025. The company’s pipeline advanced meaningfully with pivotal Phase III data for olezarsen, showing unprecedented reductions in triglycerides and acute pancreatitis events in severe hypertriglyceridemia (sHTG), leading to a breakthrough therapy designation and an anticipated launch by mid-2026.